It seems that every year�AMD (NYSE: AMD ) makes a pretty large fuss about a next-generation mobile product, but year after year these products don't materialize in many shipping designs. Some argue that the same argument could be applied to larger PC chip rival Intel (NASDAQ: INTC ) , but there are numerous quality Windows-based tablets shipping with Intel silicon, even if Intel's Bay Trail on Android continues to be MIA. So a simple question that AMD investors should try to answer is: Where are all of the AMD tablets?
A trip to AMD's website: Trying to buy an AMD tablet
To see what kind of progress AMD has made in securing tablet designs, a trip to AMD's website is in order. Clicking on the "where to buy" button on AMD's tablet page reveals some interesting results. Of the 10 tablets available in total, the breakdown by chip is as follows:
Of the four dual-core A4 based devices, three were 11.6-inch designs and one was a 13.3-inch detachable Windows 8 PC. Not a single one was a "tablet" in the sense of a traditional 10.1-inch or 9.7-inch design. Of the quad-core A6 based devices, all three were 13.3-inch designs from Hewlett-Packard. And naturally, the older Z-series APU based designs weren't anything to write home about, particularly as reviews panned both the performance and battery lives of products based on this chip (since the chip was unsuitable for thin and light tablets).
Top 5 Electric Utility Companies To Own In Right Now: Durata Therapeutics Inc (DRTX)
Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.
As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.
The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.
Advisors' Opinion:- [By Bob's Stocks]
Durata Therapeutics (DRTX) is developing Dalbavancin, a once a week, intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. The company is expected to file a NDA (New Drug Application) at any moment and MAA (Marketing Authorization Application) at the end of 2013.
- [By Lisa Levin]
Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.
5 Best Shipping Stocks To Buy For 2014: Conatus Pharmaceuticals Inc (CNAT)
Conatus Pharmaceuticals Inc., incorporated on July 13, 2005, is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company�� initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).
The Company has completed two placebo-controlled Phase II trials in patients with liver disease showing reductions in ALT levels that occur rapidly, within as little as one day after initiation of therapy, and are maintained throughout the treatment period. In the Company�� 204-patient Phase 2b trial, it also measured cCK18, an important biomarker of apoptosis and disease severity. Emricasan has been generally well-tolerated in all of the clinical studies. As of July 23, 2013, the Company had not generated any revenue.
Advisors' Opinion:- [By John Udovich]
Recent IPO�FibroGen Inc (NASDAQ: FGEN) surged 22.96% today, reportedly after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD) which laid out criteria for a phase three study of a treatment for non-alcoholic steatohepatitis (NASH)���meaning its worth taking a closer look at the stock along with the performance of potential small cap or mid cap liver disease stock peers like Conatus Pharmaceuticals Inc (NASDAQ: CNAT), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Raptor Pharmaceutical Corp (NASDAQ: RPTP) which rose 24.35%, 10.98% and 2.02%, respectively. According to Investors Business Daily, NASH (the more serious version of fatty liver disease) is potentially an enormous market with about 6 million�US patients but the�lack of previous treatments had left it unclear how the FDA would measure success against the disease while FibroGen Inc doesn't yet have a NASH human trial in the works, it has said it hopes to start one for its lead candidate FG-3019 (its in mid-stage trials for pulmonary fibrosis and liver fibrosis due to hepatitis B infection).
- [By Lauren Pollock]
Conatus Pharmaceuticals Inc.'s(CNAT) shares jumped 26% to $7.75 premarket after the biotechnology firm said its treatment for chronic liver disease has been granted a status that could mean quicker approval.
- [By John Udovich]
While Intercept Pharmaceuticals Inc (NASDAQ: ICPT) surged earlier this year and Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) has surged this week after Merck & Co. Inc (NYSE: MRK) agreed to purchase hepatitis stock�Idenix Pharmaceuticals Inc (NASDAQ: IDIX) at a 239% premium, it seems the herd has realized that small cap Conatus Pharmaceuticals Inc (NASDAQ: CNAT) is also a liver disease stock as shares suddenly surged 56.69% on no apparent company news. But just what is�Conatus Pharmaceuticals and is it worth taking a chance on?
5 Best Shipping Stocks To Buy For 2014: Kellogg Co (K)
Kellogg Company (Kellogg), incorporated in 1922, is engaged in the manufacture and marketing of ready-to-eat cereal and convenience foods. Kellogg�� principal products are ready-to-eat cereals and convenience foods, such as cookies, crackers, toaster pastries, cereal bars, fruit-flavored snacks, frozen waffles and veggie foods. As of February 28, 2012, these products were, manufactured by the Company in 17 countries and marketed in more than 180 countries. It also markets cookies, crackers, and other convenience foods, under brands, such as Kellogg��, Keebler, Cheez-It, Murray, Austin and Famous Amos, to supermarkets in the United States. Its cereal products are generally marketed under the Kellogg�� name and are sold principally to the grocery trade through direct sales forces for resale to consumers. Effective June 1, 2012, Procter & Gamble Co announced that it has completed the sale of its Pringles business to Kellogg.
As of February 28, 2012, Kellogg operated manufacturing plants and distribution and warehousing facilities totaling more than 30 million square feet of building area in the United States and other countries. Its manufacturing facilities in the United States include four cereal plants and warehouses located in Battle Creek, Michigan; Lancaster, Pennsylvania; Memphis, Tennessee; Omaha, Nebraska and other plants or facilities in San Jose, California; Atlanta, Augusta, Columbus, and Rome, Georgia; Chicago, Illinois; Seelyville, Indiana; Kansas City, Kansas; Florence, Louisville, and Pikeville, Kentucky; Grand Rapids and Wyoming, Michigan; Blue Anchor, New Jersey; Cary and Charlotte, North Carolina; Cincinnati, West Jefferson, and Zanesville, Ohio; Muncy, Pennsylvania; Rossville, Tennessee; Clearfield, Utah; and Allyn, Washington. As of February 28, 2012, outside the United States, the Company had, additional manufacturing locations, some with warehousing facilities, in Australia, Brazil, Canada, Colombia, Ecuador, Germany, Great Britain, India, Japan, Mexico, Russia, S! outh Africa, South Korea, Spain, Thailand and Venezuela.
The Company�� trademarks include Kellogg�� for cereals, convenience foods and its other products, and the brand names of certain ready-to-eat cereals, including All-Bran, Apple Jacks, Bran Buds, Cinnamon Crunch Crispix, Choco Zucaritas, Cocoa Krispies, Complete, Kellogg�� Corn Flakes, Corn Pops, Cracklin��Oat Bran, Crispix, Cruncheroos, Crunchmania, Crunchy Nut, Eggo, Kellogg�� FiberPlus, Froot Loops, Kellogg�� Frosted Flakes, Kellogg�� Krave, Frosted Krispies, Frosted Mini-Wheats, Fruit Harvest, Just Right, Kellogg�� Low Fat Granola, Mueslix, Pops, Product 19, Kellogg�� Raisin Bran, Raisin Bran Crunch, Rice Krispies, Rice Krispies Treats, Smacks/Honey Smacks, Smart Start, Kellogg�� Smorz, Special K, Special K Red Berries and Zucaritas in the United States and elsewhere; Crusli, Sucrilhos, Vector, Musli, NutriDia, and Choco Krispis for cereals in Latin America. Vive and Vector are brands in Canada; Coco Pops, Chocos, Frosties, Fruit�� Fibre, Kellogg�� Crunchy Nut Corn Flakes, Honey Loops, Kellogg�� Extra, Sustain, Muslix, Country Store, Ricicles, Smacks, Start, Pops, Optima and Tresor for cereals in Europe; and Cerola, Sultana Bran, Chex, Frosties, Goldies, Rice Bubbles, Nutri-Grain, Kellogg�� Iron Man Food, and BeBig for cereals in Asia and Australia. In additional, the Company trademarks are the names of certain combinations of ready-to-eat Kellogg�� cereals, including Fun Pak, Jumbo, and Variety.
Other Company brand names include Kellogg�� Corn Flake Crumbs; All-Bran, Choco Krispis, Froot Loops, Special K, NutriDia, Kuadri-Krispis, Zucaritas and Crusli for cereal bars, Komplete for biscuits; and Kaos for snacks in Mexico and elsewhere in Latin America; Pop-Tarts and Pop-Tarts Ice Cream Shoppe for toaster pastries; Pop-Tarts Mini Crisps for crackers; Eggo, Eggo FiberPlus and Nutri-Grain for frozen waffles and pancakes; Rice Krispies Treats for baked snacks and convenience foods; Special K! and Spec! ial K2O for flavored protein water mixes and protein shakes, and Nutri-Grain cereal bars, Nutri-Grain yogurt bars, for convenience foods in the United States and elsewhere. Brands like K-Time, Rice Bubbles, Day Dawn, Be Natural, Sunibrite and LCMs for convenience foods in Asia and Australia; Nutri-Grain Squares, Nutri-Grain Elevenses, and Rice Krispies Squares for convenience foods in Europe; Kashi and GoLean for certain cereals, nutrition bars, and mixes; TLC for granola and cereal bars, crackers and cookies; Special K and Vector for meal replacement products; Bear Naked for granola cereal, bars and trail mix and Morningstar Farms, Loma Linda, Natural Touch, Gardenburger and Worthington for certain meat and egg alternatives. It also markets convenience foods under trademarks and trade names, which include Keebler, Austin, Keebler Baker�� Treasures, Cheez-It, Chips Deluxe, Club, E. L. Fudge, Famous Amos, Fudge Shoppe, Kellogg�� FiberPlus, Gripz, Jack��, Jackson��, Krispy, Mother��, Murray, Murray Sugar Free, Ready Crust, Right Bites, Sandies, Special K, Soft Batch, Stretch Island, Sunshine, Toasteds, Town House, Vienna Creams, Vienna Fingers, Wheatables and Zesta.
The Company�� trademarks also include logos and depictions of certain animated characters in conjunction with its products, including Snap!Crackle!Pop! for Cocoa Krispies and Rice Krispies cereals and Rice Krispies Treats convenience foods; Tony the Tiger for Kellogg�� Frosted Flakes, Zucaritas, Sucrilhos and Frosties cereals and convenience foods, and Ernie Keebler for cookies, convenience foods and other products. It also includes the Hollow Tree logo for certain convenience foods; Toucan Sam for Froot Loops cereal; Dig ��m for Smacks/Honey Smacks cereal; Sunny for Kellogg�� Raisin Bran and Raisin Bran Crunch cereals, Coco the Monkey for Coco Pops cereal; Cornelius for Kellogg�� Corn Flakes; Melvin the Elephant for certain cereal and convenience foods, and Chocos the Bear, Sammy the Seal (aka Smaxey the Seal! ) for cer! tain cereal products.
Advisors' Opinion:- [By Dividends4Life]
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
GWW is trading at a premium to all four valuations above. The stock is trading at a 10.0% premium to its calculated fair value of $219.95. GWW did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
GWW earned three Stars in this section for 1.), 2.) and 3.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. The stock earned a Star as a result of its most recent Debt to Total Capital being less than 45%. GWW earned a Star for having an acceptable score in at least two of the four Key Metrics measured.
Rolling 4-yr Div. > 15% means that dividends grew on average in excess of 15% for each consecutive 4 year period over the last 10 years (2003-2006, 2004-2007, 2005-2008, etc.) I consider this a key metric since dividends will double every 5 years if they grow by 15%. The company has paid a cash dividend to shareholders every year since 1965 and has increased its dividend payments for 42 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked - [By Terry Savage]
TERRY SAVAGE: I am Terry Savage, author of the Savage Truth on Money and a frequent contributor to Money Show.com. Now I know you come here for investment advice and you get it here from the pros. Enough advice to maybe make your mind spin. Well that is what it is all about, sorting out the bulls, the bears and let me add a third category, the bulls, the bears and the chickens. Let me remind you that everybody should have a little bit of chicken money that is nothing to be ashamed of; it is money you simply cannot afford to lose. Now, whatever the proportions are depends on your intelligence, your knowledge of the markets, your stage in life and the size of your assets. Always keep in mind that having a safe bit of money set aside can help you ride through the inevitable volatility, the ups and downs and even big market declines that could take you off your investment path. If you know you have some money set aside in chicken money investments, you are far more likely to stick to your original plan and that original plan could include contributing $200, $500 or more every month to an index fund, let’s say, in your 401(k) plan. Remember, there has never been a 20-year period where you would have lost money in a diversified portfolio of large company stocks with dividends reinvested even adjusted for inflation. Those are the Ibbotson facts. Over the long run, you should come out ahead in a diversified stock market portfolio reinvesting your dividends.
- [By Jon C. Ogg]
We still have many key oil and energy companies reporting in the week ahead but we have now seen the sector leaders report earnings. Earnings previews have been prepared for the following stocks:
CME Group Inc. (NASDAQ: CME) Hertz Global Holdings Inc. (NYSE: HTZ) Kellogg Company (NYSE: K) DirecTV (NASDAQ: DTV) Office Depot Inc. (NYSE: ODP) and OfficeMax Incorporated (NYSE: OMX) Tesla Motors Inc. (NASDAQ: TSLA) T-Mobile US, Inc. (NYSE: TMUS) American Water Works Company Inc. (NYSE: AWK) Duke Energy Corp. (NYSE: DUK) QUALCOMM Inc. (NASDAQ: QCOM) Time Warner Inc. (NYSE: TWX) Whole Foods Market Inc. (NASDAQ: WFM) Groupon Inc. (NASDAQ: GRPN) Molycorp Inc. (NYSE: MCP) The Walt Disney Company (NYSE: DIS) Priceline.com Inc. (NASDAQ: PCLN) The Wendy’s Company (NYSE: WEN)CME Group Inc. (NASDAQ: CME) reports earnings on Monday morning. With all of the exchange mergers of the last decade this remains one of the dominant exchanges. Estimates are $0.73 EPS and $713.3 million in revenue. Keep in mind that this exchange is now worth $25 billion. At $74.70, the consensus analyst price target is only just barely higher at almost $75.50.
- [By Jake Zamansky]
Indeed, the NASDAQ breakdowns follow almost a litany of other technology failures on Wall Street. Those include the recently botched Facebook (FB) IPO, the May 2010 flash crash and, most recently, Goldman Sachs (GS) flooding the U.S. options market with a number of unintended computer-driven trades in companies such as JPMorgan Chase (JPM) and Kellogg (K) Company.
5 Best Shipping Stocks To Buy For 2014: Officemax Incorporated(OMX)
OfficeMax Incorporated, together with its subsidiaries, distributes business-to-business and retail office products. Its Contract segment markets and sells office supplies and paper, technology products and solutions, office furniture, and print and document services directly to large corporate and government offices, as well as to small and medium-sized offices through field salespeople, outbound telesales, catalogs, Internet, and office products stores. As of December 31, 2011, this segment operated 38 distribution centers in the United States, Puerto Rico, Canada, Australia, and New Zealand; 4 customer service and outbound telesales centers in the United States; and 47 office products stores in Canada, Hawaii, Australia, and New Zealand. The company?s Retail segment markets and sells office supplies and paper, print and document services, technology products and solutions, and office furniture to small and medium-sized businesses and consumers through a network of reta il stores. As of December 31, 2011, this segment operated 978 stores in the United States and Mexico; 3 large distribution centers in the United States; and 1 small distribution center in Mexico. The company, formerly known as Boise Cascade Corporation, was founded in 1913 and is headquartered in Naperville, Illinois.
Advisors' Opinion:- [By Michael Lewis]
Office Depot (NYSE: ODP ) scored a win in its merger with fellow big-box supply store retailer Office Max (NYSE: OMX ) , but is the company out of the proverbial weeds? The Depot saw its shares decline more than 6% Wednesday due to an earnings report that came in under estimates and altogether left investors and analysts unimpressed. No one has any delusions as to the intense technology-fueled disruption facing Office Depot and its recently acquired competitor, but there are levers the company can pull to remain relevant in the future.
- [By Rich Duprey]
For its part, Office Depot says it's a shame it had to waste money going to court to defend against Starboard's action to force an annual meeting. Since they're working on the merger with OfficeMax (NYSE: OMX ) , it was a process that had to play out. That's why they announced last week they were going to have the meeting on Aug. 21.
- [By Charley Blaine]
Shares of Office Depot (NYSE: ODP) got a boost, shooting up 3.5 percent to $5.79 after the Federal Trade Commission closed a probe of the company's proposed merger with OfficeMax (NYSE: OMX).
No comments:
Post a Comment